1. Introduction
Anemia represents a frequent complication in cancer patients as well as in chronic inflammatory diseases. It is an important cause of cancer-related fatigue [ 1 ], which considerably affects quality of life. Anemia is in fact considered as a bad prognostic factor for survival regardless of tumor type [ 2 ]. Up to 40% of cancer patients are anemic at diagnosis [ 3 , 4 ] and the frequency even increases following chemotherapy [ 5 ]. This incidence varies according to the stage and the tumor type as well as patient age. Moreover, tumor responsiveness to radiotherapy seems to be weakened in the case of anemia [ 6 ]. In substitution to blood transfusion as anti-anemia therapy, some erythroid stimulating agents have been developed including human recombinant erythropoietin (hrEpo). Despite this treatment improves quality of life by alleviating anemia, the use of hrEpo as a treatment for cancer related anemia could be inappropriate for cancer patients. Indeed, based on clinical trials [ 7 , 8 ] hrEpo was suspected to trigger tumor progression leading to decreased survival.
The essential role of circulating erythrocytes is the transport of oxygen to the tissues. Oxygen is bound to hemoglobin within erythrocytes that makes them highly prone to oxidative damage [ 9 ]. For this reason, erythroid cells contain numerous antioxidant enzymes to protect them against oxygen radicals [ 10 ] and deficient protection from reactive oxygen species (ROS) results in disease of red blood cells including anemia [ 11 ]. In fact, there are several causes of cancer-associated anemia including mechanical influence of the tumor on blood flow, and mainly the immune system activation with autoantibody formation and pro-inflammatory cytokines production [ 12 ]. Indeed, in vivo and in vitro studies have demonstrated the implication of interferon (IFN)- γ , tumour-necrosis factor (TNF)- α , TNF-related apoptosis-inducing ligand (TRAIL) and interleukin (IL)-1 [ 13 – 18 ] in the inhibition of the proliferation, and differentiation of erythroid progenitor cells. Moreover, anemia in children with solid tumours was related to IFN γ and TNF α [ 19 ]. In fact, pro-inflammatory cytokines were shown to trigger the suppression of renal erythropoietin production and therefore erythropoiesis. Inhibition of Epo production was shown in vitro and in vivo to potentially involve IFN γ , IL-1 and -6, and TNF α [ 20 – 22 ].
However, according to Spivak [ 12 ], the suppression of erythropoietin production in inflammatory conditions such as cancers, cannot be the solely explanation for anemia since the level of plasma erythropoietin is not affected in a sufficient amount. In this respect, hematopoietic stem/progenitor cells (HSPC) express receptors for pro-inflammatory cytokines [ 12 ] and several studies demonstrated that a direct action of the cytokines on hematopoietic cell lines in vitro could impair erythroid development and the number of erythroid progenitor cells [ 23 – 26 ]. Moreover, cytokines act in a microenvironment where they are produced and supposed to be concentrated, rather than in circulating blood. Indeed, poor correlation has been reported between circulating cytokine levels and the high cellular cytokine production [ 27 ]. Furthermore, marrow-adherent cells from patients with the anemia of chronic disease suppressed erythroid progenitors [ 28 ]. The molecular mechanisms involved in pro-inflammatory cytokine-mediated anemia, apart from Epo down-regulation and iron metabolism deficiency, are poorly described. For that reason, we aim to review the current knowledge concerning the direct effect of pro-inflammatory cytokines on erythroid cell differentiation, especially on signal transduction pathways and the regulation of erythrospecific genes expression in the pro-inflammatory-mediated inhibition of erythroid differentiation. We will then focus on molecular regulation of erythroid differentiation rather than on iron or erythropoietin involvement in anemia.
2. Molecular Regulation of Erythroid Differentiation
Expansion and differentiation of erythroid progenitor cells are dependent on growth factors and hormones network, acting in a thinly regulated chronology. Epo is the main erythropoietic hormone, acting by interaction with its specific membrane receptor EpoR. Stimulation of EpoR triggers the activation of signaling pathways required for survival, proliferation, and differentiation of erythroblasts. Another important cytokine involved in erythropoiesis is the stem cell factor (SCF), a ligand of the membrane receptor c-Kit. Signal transduction pathways activated by SCF have been reported to delay differentiation and to enhance progenitors proliferation in cooperation with Epo [ 29 , 30 ].
EpoR is a homodimer constitutively associated with Janus tyrosine kinase 2 (Jak2). The activation of Jak2 results from the ligand binding-induced conformational change of the EpoR dimer [ 31 , 32 ]. Activated Jak2 induces phosphorylation of the tyrosine kinase RON that activates PI3K via the docking molecule Grb2-associated binder (Gab)1 [ 33 ] also reported as phosphorylated after stimulation of EpoR [ 34 ]. Activation of the PI3K substrate AKT/PKB induces downregulation of the cell cycle inhibitor p27/kip1 expression [ 35 ] via inhibition of the transcription factor forkhead box 03a (FOXO3a) [ 36 ], a downstream target of EpoR/PI3K/AKT signaling pathway. Moreover, the transcription factor FOXO3a has been recently reported as one of the main regulators of oxidative stress in erythropoiesis [ 37 ]. In fact, FOXO3a is inactivated by Epo signaling pathway and its expression as well as its transcriptional activity is enhanced during the maturation of erythroid precursor cells when EpoR expression decreases. In the presence of Epo and in the case of the loss of FOXO3a, ROS mediate the decrease in lifespan of circulating erythrocytes as well as the rate of erythroid cell maturation. This suggested that FOXO3 is required for the regulation of oxidative stress in erythropoiesis.
The cell-signaling cascade initiated by Epo-dependent Jak2 activation, leads to erythroblast expansion. Moreover, PI3K activation mediates the mitogen-activated protein kinase (MAPK, ERK1/2) path in correlation with the expansion of erythroblasts [ 38 ]. Another EpoR-mediated pathway leading to cell proliferation involves the Ras-Raf-MEK-ERK pathway [ 39 – 43 ] upon recruitment of the Grb2-Sos adapter molecules to the EpoR [ 44 , 45 ]. Phosphorylation of the kinase Raf1 [ 39 ] has been shown to delay erythroblast differentiation by restraining the caspase-3 activation [ 46 ]. Moreover, EPO and SCF activate Jun-N terminal kinase (JNK) promoting proliferation and survival of hematopoietic cells [ 47 , 48 ].
On the other hand, Epo-induced differentiation of erythroid cells is also dependent on PI3K/Akt signaling pathway that was suggested to act in concert with protein kinase C (PKC)- α [ 49 ]. PKC- α isoform has a role in mediating EPO-induced erythroid differentiation of the CD34+ progenitor cells from human bone marrow [ 50 ]. Furthermore, during Epo-dependent phase of erythroid differentiation, Epo and SCF suppressed activity of p38 α whereas during the Epo-independent terminal-phase of differentiation, p38 α and - δ phosphorylation was increased. This demonstrated both isoforms of p38 function to promote the late-stage differentiation of primary erythroid progenitors [ 51 ]. This confirmed previous report, showing that activation of p38 as well as JNKs was required for Epo-induced erythroid differentiation in SKT6 cells [ 52 ].
Also involved in erythropoiesis regulation is the Jak/STAT5 signaling pathway which is rapidly activated after Epo binding to EpoR, on erythroid progenitors. In mice models, it was shown that early erythroblasts survival as well as normal erythropoiesis was controlled by STAT5 [ 53 ]. Indeed, silenced STAT5 expression in mice led to an increase in early erythroblast numbers which nevertheless failed to progress in differentiation giving rise to anemia. Silenced STAT5-mediated anemia was correlated to down-regulation of the antiapoptotic bcl-X L gene and to increased apoptosis. This supported the Jak/STAT5 pathway implication in the regulation of differentiation by preventing pro-erythroblasts apoptosis. On the other hand, bcl-X L -mediated inhibition of apoptosis in erythroid cells was shown to be a response to Epo/EpoR-induced inhibition of the caspase cascade amplification [ 54 ]. Indeed, caspase-3 activation led to degradation of the transcription factors SCL/TAL-1 as well as GATA-1, which regulate bcl-X L gene expression [ 54 , 55 ]. In fact, Tal-1 protein was shown phosphorylated in response to Epo stimulation [ 56 ] by PI3K-activated MAPK signaling pathway [ 57 ].
Stimulation of signaling pathways by Epo/EpoR, SCF/Kit or other stress conditions results in the activation/repression of many transcription factors specifically involved in erythropoiesis regulation. The zinc finger protein GATA-1 is considered as one of the most critical transcription factors in erythropoiesis as well as megakaryopoiesis. Besides GATA-1 that belongs to the GATA-family of transcription factors, GATA-2 is also involved in erythropoiesis and megakaryopoiesis regulation [ 58 , 59 ]. Both GATA-1 and GATA-2 transactivation activities require interaction with friend of GATA (FOG)-1 cofactor [ 60 , 61 ]. In addition, both transcription factors have GATA binding sites in their cis -acting elements allowing a cross-regulatory mechanism in which GATA-1 can control the expression of GATA-2 and vice versa. GATA-2 is overexpressed in early immature hematopoietic progenitors to ensure their maintenance and proliferation whereas GATA-1 is essential for the survival of erythroid progenitors as well as the terminal differentiation of erythroid cells [ 59 , 62 ]. In fact, increased expression of GATA-2 determines megakaryocytic differentiation whereas its down-regulation is required for erythroid differentiation [ 58 ]. Recently, a role for GATA-2 in the regulation of quiescence in human hematopoietic stem and progenitor cells has been reported [ 63 ]. GATA-1 activation has been correlated to its phophorylation. Epo-induced phosphorylation of GATA-1 is important for maturation of fetal liver erythroid progenitor cells, specifically on serine 310 by PI3K/AKT that enhances GATA-1 transcriptional activity in vitro and in erythroid cells [ 64 ]. However, GATA-1 acetylation by CBP/p300 is also described as crucial for the binding to its DNA target GATA sequence possibly involving phosphorylation [ 65 – 67 ]. Moreover, phosphorylation of GATA-1 could be mediated by MAPK pathway, as an ubiquitination signal for its proteasomal degradation [ 68 ]. On the other hand, besides FOG1, GATA-1 activity is highly dependent on interaction with many cofactors including EKLF, SP1, CBP/p300, Lmo2, Ldb1, RUNX1, Fli1 and PU.1, which represent a part of the best-described interacting proteins. These cofactors can constitute a very complex network regulating erythropoiesis and megakaryopoiesis, by promoting or repressing GATA-1 activity [ 69 – 73 ]. Particularly, PU.1 is a strong inhibitor of GATA-1 DNA-binding activity and erythroid differentiation [ 74 , 75 ].
3. TNF α Directly Inhibits Erythropoiesis
Evidences for TNF α inhibiting effect on erythroid differentiation have been described 30 years ago. In 1987 Blick et al. observed a decrease in hemoblobin synthesis in cancer patients treated with TNF α (phase 1) [ 13 ] while in vitro study showed that TNF α inhibited the formation of BFU-E cells [ 28 ]. Later, Xiao et al. reported that TNF α inhibited the glycophorin A+ cells in correlation with an inhibition of erythropoiesis [ 76 ]. Moreover, an increasing hemoglobin level has been observed in patients suffering from anemia of chronic disease after an anti-TNF treatment [ 77 ]. The reduction of Epo production in the kidney partially explained the effect of the pro-inflammatory cytokins including TNF α [ 20 ]. La Ferla et al. reported that TNF α -mediated inhibition of Epo production in HepG2 cells was a consequence of GATA-2 and NF- κ B over-expression [ 78 ]. This was to some extent completed by Imagawa et al. who showed that TNF α -mediated inhibition of Epo gene expression could be rescued by the K-7174, a “GATA-specific inhibitor,” in HepG3 cells [ 79 ]. However, TNF α inhibiting effect on erythroid differentiation also occurs by a direct action on cells, including hematopoietic progenitors and cell lineages. Recently, Tsopra et al. published a study on disease-related anemia in chronic lymphocytic leukemia (CLL) patients. They showed that CLL-related anemia might result from the direct suppressive effect of TNF α on the erythroid development in early stages of erythropoiesis instead of an intrinsic defect of erythroid precursors to differentiate or to respond to Epo stimulation [ 80 ]. In fact, the results from Rusten and Jacobsen in 1995 suggested for the first time that TNF- α -induced inhibition of erythroid colony formation could be directly mediated on the progenitor cells [ 26 ]. By using BFU-E colony stimulated by various cytokine combinations (SCF, IL-3, IL-9) with Epo, they showed that TNF α inhibiting effect was mediated predominantly through p55-TNF receptor (TNFR1). This result was correlated to the implication of NF- κ B transcription factor, a TNF α /TNFR1 activated product, in the inhibition of erythroid specific genes. Especially, transfection assays in K562 cells showed the suppression of human α -like globin promoters by the NF- κ B pathway [ 81 ] . On the other hand, our group recently showed that TNF α inhibited hemoglobin production in aclacinomycin-induced K562 cells [ 25 ]. Aclacinomycin is an anthracyclin that was reported to induce over-expression of the key transcription factors for erythropoiesis, GATA-1 and NF-E2 in this cell line [ 82 , 83 ]. Interestingly, the cytokine inhibiting effect was correlated to the down-regulation of GATA-1 and NF-E2. These results were confirmed in the erythroleukemia cell lines HEL and TF-1 [ 23 , 24 ]. Furthermore, studies in K562 and HEL cells strongly suggested GATA-1 as a key target of TNF α inhibiting effect achievement ( Figure 1 ). Indeed, the cytokine induced a decrease in the expression of FOG-1, an essential cofactor of GATA-1, a down-regulation of GATA-1 by proteasomal degradation and a reduced acetylation level of GATA-1 while the transcription factor GATA-2 was over-expressed [ 24 ]. In addition, an inhibition of EpoR, α - and γ -globin, erythroid-associated factor (ERAF), hydroxymethylbilane synthetase (HMBS), and glycophorin A (GPA) erythro-specific genes, was found in the Epo-dependent TF-1 cell line [ 23 ]. These results were concomitant with a reduction of GATA-1/FOG-1 complex formation and a significant and rapid increase in p38MAPK phosphorylation. The inhibition of p38 abrogated the inhibitory effect of TNF α on GATA-1 as well as γ -globin expression in Epo-induced TF-1 cells.
Thus, data related to TNF α -mediated inhibition of erythropoiesis show the indirect but also the direct involvement of this cytokine in anemia development. However despite few publications describe the molecular mechanisms implicated, they clearly show the role of TNFR1 and NF- κ B, as well as other specific transcription factors, namely GATA-1 and FOG1, NF-E2, and GATA-2. Notably, the down-regulation of GATA-1 at different levels by TNF α might affect erythroblasts programmed cell death besides differentiation, by triggering early apoptosis via down-expression of the anti-apoptic bcl-X L gene whose transcription is regulated by GATA-1. Obviously, TNF α causes anemia independently of inhibition of Epo production. Further studies on molecular mechanisms using hematopoietic stem/progenitor cells should allow bettering understanding of how TNF α -mediated inhibition of erythropoiesis occurs.
4. TRAIL-Mediated Anemia Involves Apoptosis
TNF-related apoptosis-inducing ligand (TRAIL), also known as Apo2L, is a member of the TNF-related proteins initially identified and characterized by Wiley et al. in 1995. It is a type II membrane protein that is also expressed as a soluble protein. Both forms are able to induce apoptosis in a wide variety of transformed cell lines of diverse origins [ 84 ] including several hematopoietic lineages [ 85 ]. TRAIL exhibits structural and functional similarities with Fas ligand (FasL/CD95L), including the use of FADD as adaptor molecule [ 86 – 90 ]. It interacts with four high-affinity membrane receptors (R) TRAIL-R1 (DR4), TRAIL-R2 (DR5), TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2) that belong to the apoptosis inducing TNF-receptor family. A study on TRAIL implication in the homeostatic control of hematopoiesis showed its negative effect on normal erythropoiesis, in a differentiation-stage specific manner [ 18 ].
Moreover, studies on TRAIL activity and expression in myelodysplastic syndromes (MDS) patients have been reported. MDS are characterized by impaired erythropoiesis leading to anemia, the major clinical feature in this syndrome. By analyzing MDS marrow, Zang et al. showed that TRAIL induced extensive apoptosis, including in the blast cell population while no increase in apoptosis was observed in normal marrow [ 91 ]. They correlated this observation with high levels of surface expression of agonistic receptors TRAIL-R1 and -R2 in MDS marrow, which could explain the selective killing of tumor cells by TRAIL. On the other hand, the authors suggested that apoptotic response could be modified by the variations in the anti-apoptotic protein FLIP expression in addition to the cell-surface-receptor expression in MDS. Indeed, they found that FLIP was expressed in marrow from healthy donors whereas the protein was not detectable in most of the MDS marrows. Together, the results suggested that TRAIL might play a role in the regulation of hematopoiesis in MDS marrow. In the same way, another study showed that TRAIL expression was increased in the bone marrow mononuclear cells from MDS patients and released at the bone marrow level probably contributing to the degree of anemia. In fact, MDS bone marrow-conditionned media with released soluble TRAIL, added to a normal CD34-derived erythroblasts culture, led to impairment of erythroid maturation, as assessed by the levels of GPA. This demonstrated the role of soluble TRAIL in affecting the maturation of erythroid precursors in MDS patients [ 92 ].
A comparative study in multiple myeloma (MM) patients with or without anemia, showed an inverse correlation between the expression of TRAIL (and Fas-L) in malignant plasma cells and the relative erythroblast numbers, with a higher percentage of immature erythroblasts in enriched erythroblast populations from anemic MM patients [ 93 ]. A downexpression of GATA-1 transcription factor has been detected in immature erythroblasts from MM patients with severe anemia. They ascribed this decrease to Fas-L and/or TRAIL-mediated cleavage of GATA-1 native form. Indeed, GATA-1 can be cleaved by several caspases in CD34+ cell-derived erythroblasts, following their treatment with TRAIL leading to maturative arrest [ 55 ].
Secchierro et al. found that TRAIL-R3 and -R4 were never expressed neither on the surface of freshly purified CD34+ hematopoietic progenitor cells nor on GPA+ erythroblasts at early-intermediate and late culture times [ 94 ]. On the contrary, they suggested that TRAIL-R2 probably played a role in erythroid development since this receptor was found expressed at early phases of erythroid differentiation with a progressive increase along the erythroid maturation. Conversely, TRAIL-R1 was detectable only at early phases of erythroid development. The authors reported that TRAIL induced MAP kinase ERK1/2 activation in primary normal erythroblasts, but not p38 or JNK. Considering that ERK1/2 pathway was shown as involved in the early proliferative phases of erythropoiesis [ 95 ] and in the inhibition of terminal erythroid differentiation [ 52 , 96 – 98 ], they suggested that TRAIL-mediated activation of ERK1/2 was responsible for the inhibiting effect of TRAIL on normal erythroid development. On the other hand, the activation of ERK1/2 by TRAIL at all the stages of erythroid development correlated with the expression of TRAIL-R2. Together these studies clearly indicate that TRAIL plays a role in erythropoiesis inhibition and anemia development via its receptor R2 and probably R1.
5. Indirect Action of Interferon-Gamma
Interferon (IFN)- γ has been reported as inhibiting growth and differentiation of erythroid precursor cells [ 99 , 100 ] as well as a potential mediator of hematopoietic failure in aplastic anemia (AA). AA belongs to the bone marrow failure syndromes, characterized by a breakdown in the stem- and progenitor-cell compartments. In fact, several authors had suspected the role of IFN- γ in erythropoiesis inhibition according to an elevated production of the cytokine by lymphocytes in AA patients while it was absent in normal bone marrow [ 100 – 105 ]. A microarray analysis of RNA-expression profile in CD34+ and bone marrow stroma cells showed that IFN- γ induced an increase in the expression of Fas and TRAIL genes, known to be involved in anemia promotion [ 106 ]. Furthermore, Felli et al. reported that the TNF family members TRAIL and TWEAK (Apo-3 ligand) as well as its receptor Fn-14 were involved in IFN- γ -mediated suppression of erythropoiesis in purified human erythroblasts [ 107 ]. This was in correlation with the inhibition of growth and differentiation of the erythroblasts. Moreover, they could restore erythroid cell survival, proliferation and maturation, inhibited by IFN- γ , performing combined neutralization of TWEAK, TRAIL and FasL/CD95L. This pointed out the role of the three proteins as effectors of IFN- γ in erythropoiesis suppression. On the other hand, the modulation of adhesion molecule genes expression (ICAM1 and VCAM1, integrin- α 5 and integrin- β 3) in stromal cells treated with IFN- γ [ 106 ] correlated with previous works demonstrating the altering effect of IFN- γ (and TNF- α ) on the adhesive mechanism [ 108 ]. Therefore it was assumed that the cytokine may affect the function of bone hematopoietic stem cells by disturbing their adhesion to the marrow microenvironment in AA patients [ 106 ]. Until now, in opposition to TNF α and TRAIL, the direct effect of IFN- γ on erythroblastic cells at the molecular level has not been demonstrated. However, IFN- γ and also IL-6 are known to activate the phosphorylation of the transcription factor STAT3. It was recently reported that STAT3 activation silenced γ -globin gene expression in primary erythroid cells [ 109 ] and foetal hemoglobin production in K562 cells. In these experiments the effect of STAT3 was reversed by GATA-1 induced over-expression [ 110 ].
6. Inflammation, Oxidative Stress and Anemia
One of the major proteins of red blood cells is the acidic peroxidoxin, which plays a role in the response against oxidative stress. The expression of this protein is induced early in erythropoiesis, prior to hemoglobin production suggesting the importance of the protection of erythroid progenitors against oxidative stress [ 111 ]. Erythropoiesis regulation is indeed very sensitive to oxidative stress and the release of proinflammatory cytokines in neoplastic patients as well as chronic inflammatory diseases are often associated with increased production of reactive oxygen species (ROS) (H 2 O 2 and HO ∙ ) [ 112 , 113 ]. Moreover, TNF α links inflammation to carcinogenesis through ROS [ 114 ] and it was reported that TNF α elevates ROS production in glioma cells [ 115 ]. However, it appears that the role of oxidative stress is complex since reactive oxygen species may either trigger [ 116 ] or prevent [ 117 , 118 ] hematopoietic differentiation and proliferation. It was demonstrated that the increase in oxidative stress and free radicals are associated with disorders implicated in anemia of chronic disease [ 119 ] while anthracycline- and butyrate-mediated differentiation of K562 cells was prevented by anti-oxidant compounds [ 120 ]. This last study suggested that butyrate- or anthracycline-generated oxidative stress was involved as the first step in the irreversible erythroid differentiation process. On the other hand, Dallalio et al. reported that inflammatory cytokine-mediated anemia of chronic disease may occur through modulation of oxidative stress [ 121 ]. Elorza et al. also demonstrated the importance of the ROS modulation during erythropoiesis, by studying the uncoupling protein (UCP)2 role [ 122 ]. Its expression leads to a decrease in mitochondrial superoxide and it was previously shown that UCP2 was related to erythroid differentiation since it was induced by GATA-1 activation in the proerythroblast G1E-ER cell line [ 123 ]. UCP2 deficiency in progenitor cells at the Epo-dependent phase of erythropoiesis led to a decrease in cell proliferation in correlation with ERK reduced phosphorylation, which is known as a ROS-dependent cytosolic regulator of cell proliferation. A relationship between UCP2 and the MAPK/ERK pathway has been reported in the case of elevated inflammatory response and inhibition of UCP2 could lead to the development of anemia [ 124 ].
7. Conclusions
Obviously pro-inflammatory cytokines have a negative effect on erythropoiesis development leading to anemia in multiple diseases including chronic infections, chronic inflammatory diseases, myelodysplastic syndromes, and malignancy. The pathophysiological effects of cytokine over-expressions have been well described but the mechanisms surrounding cytokine-mediated induction of anemia remain largely unknown. Many studies show that erythroid colony formation in response to Epo is impaired in the presence of pro-inflammatory cytokines [ 125 – 127 ] without providing molecular mechanisms. In this paper we review data available on the molecular mechanisms involved in the defect of erythropoiesis due to three pro-inflammatory cytokines TNF α , TRAIL, and IFN γ . Nonetheless, other pro-inflammatory cytokines have been involved in erythropoiesis defect, such as the interleukin (IL)-6 [ 112 ]. Impaired erythropoiesis is most likely due to apoptosis induction, cell growth inhibition and EpoR downregulation as a result of a local increased production of the cytokines, but also iron metabolism damage. In all cases pro-inflammatory cytokines affect Epo either by inducing inhibition of its production by kidney or by preventing its physiological functions at the cellular level. Indeed, cytokines activate signaling pathways that can have common feature with EpoR-triggered signaling pathways leading to cell proliferation, differentiation, or survival.
Regulation of erythropoiesis occurs in a tightly time dependent manner and changes in the timing of one specific signaling intermediate activation can disturb cell differentiation process. Thus, it is known that both TNF α and Epo activate p38MAPK phosphorylation. We could recently observe that this kinase was very early activated by TNF α (10 minutes) while Epo-mediated activation occurred much later in TF-1 cells (48 hours). This result was correlated to the inhibiting effect of TNF α on Epo-induced erythroid differentiation in TF-1 cells [ 23 ]. Thus, how specific signal transduction pathways of pro-inflammatory cytokines can interact with EpoR ones to prevent erythroid differentiation is an interesting issue. On the other hand, pro-inflammatory cytokines activate diverse transcription factors that can have contradictory effects in regard to the cell intention. For example, NF- κ B, which is typically activated by cytokines, was reported involved in the inhibition of Epo production [ 78 ] and the repression of globin genes expression [ 81 ]. Moreover, GATA-1/GATA-2 balance, which is a key element for erythropoiesis regulation was shown affected by TNF α [ 24 ].
On the other hand, besides erythroid genes expression, GATA-1 and TAL-1/SCL are implicated in apoptosis regulation by controlling bcl-X L gene expression. Common pro-apoptotic properties of pro-anemia cytokines seem involved in erythropoiesis delay or prevention. Therefore, cytokine-mediated activation of caspases and Epo-induced GATA-1 expression might represent a crossing point in which GATA-1 cleavage would lead to down-regulation of Bcl-Xl expression and then apoptosis activation. Studying the pro-inflammatory cytokines effect at the transcriptional level should allow understanding how the erythroid specific genes are repressed and how the pro-apoptotic genes are activated. In addition to transcription factors network analysis, especially GATA-1, micro-RNAs implication could be taken in consideration according to the expected role of these molecules in erythropoiesis [ 128 – 135 ].
In conclusion, the modulation of Epo-mediated signaling pathways as well as transcription factors and cofactors by pro-inflammatory cytokines are required to achieve inhibition of erythroid differentiation. Several in vitro and in vivo studies demonstrated that high levels of proinflammatory cytokines and increased oxidative stress contribute both to the development of anemia and to the resistance to recombinant human hrEpo. The complexity of this phenomenon provides multiple targets for potential drugs in order to inhibit cytokines effect and/or to promote erythroid differentiation, mainly in cancer-related anemia. Indeed, despite hrEpo is clinically efficient for anemia treatment it is strongly suspected to induce tumor cell proliferation. Therefore studies of the mechanisms involved in the inhibiting effect of cytokines on erythropoiesis are essential to intend future anti-anemic treatment, at least for cancer patients.
Acknowledgments
Dr Diederich's research at the Laboratoire de Biologie Moléculaire et Cellulaire du Cancer (LBMCC) is financially supported by “Recherche Cancer et Sang” foundation, by the “Recherches Scientifiques Luxembourg”association, by “Een Häerz fir kriibskrank Kanner” association, by the Action Lions “Vaincre le Cancer” association and by Télévie Luxembourg. Printing costs are covered by a grant of the Fondas National pour la Recherche, Luxembourg.
1 Stasi R Abriani L Beccaglia P Terzoli E Amadori S Cancer-related fatigue: evolving concepts in evaluation and treatment Cancer 2003 98 9 1786 1801 14584059 10.1002/cncr.11742
2 Caro JJ Salas M Ward A Goss G Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review Cancer 2001 91 12 2214 2221 11413508
3 Knight K Wade S Balducci L Prevalence and outcomes of anemia in cancer: a systematic review of the literature American Journal of Medicine 2004 116 7, supplement 1 11 26 10.1016/j.amjmed.2003.12.008 15050883
4 Tas F Eralp Y Basaran M Anemia in oncology practice: relation to diseases and their therapies American Journal of Clinical Oncology 2002 25 4 371 379 12151968 10.1097/00000421-200208000-00011
5 Groopman JE Itri LM Chemotherapy-induced anemia in adults: incidence and treatment Journal of the National Cancer Institute 1999 91 19 1616 1634 10511589 10.1093/jnci/91.19.1616
6 Glaser CM Millesi W Kornek GV Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx International Journal of Radiation Oncology 2001 50 3 705 715 10.1016/s0360-3016(01)01488-2 11395239
7 Henke M Laszig R Rube C Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial The Lancet 2003 362 9392 1255 1260 10.1016/S0140-6736(03)14567-9 14575968
8 Leyland-Jones B Breast cancer trial with erythropoietin terminated unexpectedly Lancet Oncology 2003 4 8 459 460 12901958 10.1016/s1470-2045(03)01163-x
9 Winterbourn CC Oxidative denaturation in congenital hemolytic anemias: the unstable hemoglobins Seminars in Hematology 1990 27 1 41 50 2405495
10 Johnson RM Goyette G Jr. Ravindranath Y Ho Y-S Hemoglobin autoxidation and regulation of endogenous H 2 O 2 levels in erythrocytes Free Radical Biology and Medicine 2005 39 11 1407 1417 16274876 10.1016/j.freeradbiomed.2005.07.002
11 Friedman JS Rebel VI Derby R Absence of mitochondrial superoxide dismutase results in a murine hemolytic anemia responsive to therapy with a catalytic antioxidant Journal of Experimental Medicine 2001 193 8 925 934 11304553 10.1084/jem.193.8.925 PMC2193409
12 Spivak JL The anaemia of cancer: death by a thousand cuts Nature Reviews Cancer 2005 5 7 543 555 15965494 10.1038/nrc1648
13 Blick M Sherwin SA Rosenblum M Gutterman J Phase I study of recombinant tumor necrosis factor in cancer patients Cancer Research 1987 47 11 2986 2989 3567916
14 Dai C-H Price JO Brunner T Krantz SB Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon γ to produce erythroid cell apoptosis Blood 1998 91 4 1235 1242 9454753
15 Johnson RA Waddelow TA Caro J Oliff A Roodman GD Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice Blood 1989 74 1 130 138 2752104
16 Means RT Jr. Dessypris EN Krantz SB Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon Journal of Cellular Physiology 1992 150 1 59 64 1730787 10.1002/jcp.1041500109
17 Moldawer LL Marano MA Wei H Cachectin/tumor necrosis factor- α alters red blood cell kinetics and induces anemia in vivo FASEB Journal 1989 3 5 1637 1643 2784116 10.1096/fasebj.3.5.2784116
18 Zamai L Secchiero P Pierpaoli S TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis Blood 2000 95 12 3716 3724 10845902
19 Ek T Mellander L Abrahamsson J Interferon γ and tumour necrosis factor α in relation to anaemia and prognosis in childhood cancer Acta Paediatrica 2005 94 4 435 437 16092457 10.1111/j.1651-2227.2005.tb01914.x
20 Faquin WC Schneider TJ Goldberg MA Effect of inflammatory cytokines on hypoxia-induced erythropoietin production Blood 1992 79 8 1987 1994 1373333
21 Frede S Fandrey J Pagel H Hellwig T Jelkmann W Erythropoietin gene expression is suppressed after lipopolysaccharide or interleukin-1 β injections in rats American Journal of Physiology 1997 273 3, part 2 R1067 R1071 9321887 10.1152/ajpregu.1997.273.3.R1067
22 Vannucchi AM Grossi A Rafanelli D Statello M Cinotti S Rossi-Ferrini P Inhibition of erythropoietin production in vitro by human interferon gamma British Journal of Haematology 1994 87 1 18 23 7947242 10.1111/j.1365-2141.1994.tb04864.x
23 Buck I Morceau F Cristofanon S Tumor necrosis factor α inhibits erythroid differentiation in human erythropoietin-dependent cells involving p38 MAPK pathway, GATA-1 and FOG-1 downregulation and GATA-2 upregulation Biochemical Pharmacology 2008 76 10 1229 1239 18805401 10.1016/j.bcp.2008.08.025
24 Buck I Morceau F Cristofanon S Reuter S Dicato M Diederich M The inhibitory effect of the proinflammatory cytokine TNF α on erythroid differentiation involves erythroid transcription factor modulation International Journal of Oncology 2009 34 3 853 860 19212691 10.3892/ijo_00000212
25 Morceau F Schnekenburger M Blasius R Buck I Dicato M Diederich M Tumor necrosis factor alpha inhibits aclacinomycin A-induced erythroid differentiation of K562 cells via GATA-1 Cancer Letters 2006 240 2 203 212 16274927 10.1016/j.canlet.2005.09.014
26 Rusten LS Jacobsen SEW Tumor necrosis factor (TNF)- α directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors Blood 1995 85 4 989 996 7849320
27 Jason J Archibald LK Nwanyanwu OC Comparison of serum and cell-specific cytokines in humans Clinical and Diagnostic Laboratory Immunology 2001 8 6 1097 1103 11687446 10.1128/CDLI.8.6.1097-1103.2001 PMC96232
28 Roodman GD Bird A Hutzler D Montgomery W Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells Experimental Hematology 1987 15 9 928 935 2820776
29 Muta K Krantz SB Bondurant MC Dai C-H Stem cell factor retards differentiation of normal human erythroid progenitor cells while stimulating proliferation Blood 1995 86 2 572 580 7541668
30 von Lindern M Zauner W Mellitzer G The glucocorticoid receptor cooperates with the erythropoietin receptor and c-Kit to enhance and sustain proliferation of erythroid progenitors in vitro Blood 1999 94 2 550 559 10397722
31 Livnah O Stura EA Middleton SA Johnson DL Jolliffe LK Wilson IA Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation Science 1999 283 5404 987 990 9974392 10.1126/science.283.5404.987
32 Remy I Wilson IA Michnick SW Erythropoietin receptor activation by a ligand-induced conformation change Science 1999 283 5404 990 993 9974393 10.1126/science.283.5404.990
33 van den Akker E van Dijk T Parren-van Amelsvoort M Tyrosine kinase receptor RON functions downstream of the erythropoietin receptor to induce expansion of erythroid progenitors Blood 2004 103 12 4457 4465 14982882 10.1182/blood-2003-08-2713
34 Liu Y Rohrschneider LR The gift of Gab FEBS Letters 2002 515 1-3 1 7 11943184 10.1016/s0014-5793(02)02425-0
35 Bouscary D Pene F Claessens Y-E Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation Blood 2003 101 9 3436 3443 12506011 10.1182/blood-2002-07-2332
36 Kashii Y Uchida M Kirito K A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction Blood 2000 96 3 941 949 10910908
37 Marinkovic D Zhang X Yalcin S Foxo3 is required for the regulation of oxidative stress in erythropoiesis Journal of Clinical Investigation 2007 117 8 2133 2144 17671650 10.1172/JCI31807 PMC1934587
38 Sui X Krantz SB You M Zhao Z Synergistic activation of MAP kinase (ERK1/2) by erythropoietin and stem cell factor is essential for expanded erythropoiesis Blood 1998 92 4 1142 1149 9694701
39 Carroll MP Spivak JL McMahon M Weich N Rapp UR May WS Erythropoietin induces Raf-1 activation and Raf-1 is required for erythropoietin-mediated proliferation Journal of Biological Chemistry 1991 266 23 14964 14969 1869534
40 Chen C Sytkowski AJ Erythropoietin activates two distinct signaling pathways required for the initiation and the elongation of c-myc Journal of Biological Chemistry 2001 276 42 38518 38526 11483613 10.1074/jbc.M105702200
41 Marrero MB Venema RC Ma H Ling BN Eaton DC Erythropoietin receptor-operated Ca 2+ channels: activation by phospholipase C- γ 1 Kidney International 1998 53 5 1259 1268 9573541 10.1046/j.1523-1755.1998.00887.x
42 Mayeux P Dusanter-Fourt I Muller O Erythropoietin induces the association of phosphatidylinositol 3′-kinase with a tyrosine-phosphorylated protein complex containing the erythropoietin receptor European Journal of Biochemistry 1993 216 3 821 828 8404901 10.1111/j.1432-1033.1993.tb18203.x
43 Torti M Marti KB Altschuler D Yamamoto K Lapetina EG Erythropoietin induces p21ras activation and p120GAP tyrosine phosphorylation in human erythroleukemia cells Journal of Biological Chemistry 1992 267 12 8293 8298 1569084
44 Arcasoy MO Jiang X Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor British Journal of Haematology 2005 130 1 121 129 15982354 10.1111/j.1365-2141.2005.05580.x
45 Jacobs-Helber SM Sawyer ST Jun N-terminal kinase promotes proliferation of immature erythroid cells and erythropoietin-dependent cell lines Blood 2004 104 3 696 703 15059850 10.1182/blood-2003-05-1754
46 Kolbus A Pilat S Husak Z Raf-1 antagonizes erythroid differentiation by restraining caspase activation Journal of Experimental Medicine 2002 196 10 1347 1353 12438425 10.1084/jem.20020562 PMC2193984
47 Foltz IN Schrader JW Activation of the stress-activated protein kinases by multiple hematopoietic growth factors with the exception of interleukin-4 Blood 1997 89 9 3092 3096 9129010
48 Nagata Y Nishida E Todokoro K Activation of JNK signaling pathway by erythropoietin, thrombopoietin, and interleukin-3 Blood 1997 89 8 2664 2669 9108383
49 von Lindern M Parren-van Amelsvoort M van Dijk T Protein kinase C α controls erythropoietin receptor signaling Journal of Biological Chemistry 2000 275 44 34719 34727 10940312 10.1074/jbc.M007042200
50 Myklebust JH Smeland EB Josefsen D Sioud M Protein kinase C- α isoform is involved in erythropoietin-induced erythroid differentiation of CD34+ progenitor cells from human bone marrow Blood 2000 95 2 510 518 10627456
51 Uddin S Ah-Kang J Ulaszek J Mahmud D Wickrema A Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells Proceedings of the National Academy of Sciences of the United States of America 2004 101 1 147 152 14694199 10.1073/pnas.0307075101 PMC314153
52 Nagata Y Takahashi N Davis RJ Todokoro K Activation of p38 MAP kinase and JNK but not ERK is required for erythropoietin-induced erythroid differentiation Blood 1998 92 6 1859 1869 9731042
53 Socolovsky M Nam H-S Fleming MD Haase VH Brugnara C Lodish HF Ineffective erythropoiesis in Stat5a − / − 5b − / − mice due to decreased survival of early erythroblasts Blood 2001 98 12 3261 3273 11719363 10.1182/blood.v98.12.3261
54 Zeuner A Eramo A Testa U Control of erythroid cell production via caspase-mediated cleavage of transcription factor SCL/Tal-1 Cell Death and Differentiation 2003 10 8 905 913 12867998 10.1038/sj.cdd.4401255
55 De Maria R Zeuner A Eramo A Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1 Nature 1999 401 6752 489 493 10519553 10.1038/46809
56 Prasad KSS Jordan JE Koury MJ Bondurant MC Brandt SJ Erythropoietin stimulates transcription of the TAL1/SCL gene and phosphorylation of its protein products Journal of Biological Chemistry 1995 270 19 11603 11611 7744799 10.1074/jbc.270.19.11603
57 Tang T Prasad KSS Koury MJ Brandt SJ Mitogen-activated protein kinase mediates erythropoietin-induced phosphorylation of the TAL1/SCL transcription factor in murine proerythroblasts Biochemical Journal 1999 343 3 615 620 10527940 PMC1220593
58 Ikonomi P Rivera CE Riordan M Washington G Schechter AN Noguchi CT Overexpression of GATA-2 inhibits erythroid and promotes megakaryocyte differentiation Experimental Hematology 2000 28 12 1423 1431 11146164 10.1016/s0301-472x(00)00553-1
59 Ohneda K Yamamoto M Roles of hematopoietic transcription factors GATA-1 and GATA-2 in the development of red blood cell lineage Acta Haematologica 2002 108 4 237 245 12432220 10.1159/000065660
60 Chang AN Cantor AB Fujiwara Y GATA-factor dependence of the multitype zinc-finger protein FOG-1 for its essential role in megakaryopoiesis Proceedings of the National Academy of Sciences of the United States of America 2002 99 14 9237 9242 12077323 10.1073/pnas.142302099 PMC123124
61 Tsang AP Fujiwara Y Horn DB Orkin SH Failure of megakaryopoiesis and arrested erythropoiesis in mice lacking the GATA-1 transcriptional cofactor FOG Genes and Development 1998 12 8 1176 1188 9553047 10.1101/gad.12.8.1176 PMC316724
62 Ikonomi P Noguchi CT Miller W Kassahun H Hardison R Schechter AN Levels of GATA-1/GATA-2 transcription factors modulate expression of embryonic and fetal hemoglobins Gene 2000 261 2 277 287 11167015 10.1016/s0378-1119(00)00510-2
63 Tipping AJ Pina C Castor A High GATA-2 expression inhibits human hematopoietic stem and progenitor cell function by effects on cell cycle Blood 2009 113 12 2661 2672 19168794 10.1182/blood-2008-06-161117
64 Zhao W Kitidis C Fleming MD Lodish HF Ghaffari S Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway Blood 2006 107 3 907 915 16204311 10.1182/blood-2005-06-2516 PMC1895894
65 Blobel GA Nakajima T Eckner R Montminy M Orkin SH CREB-binding protein cooperates with transcription factor GATA-1 and is required for erythroid differentiation Proceedings of the National Academy of Sciences of the United States of America 1998 95 5 2061 2066 9482838 10.1073/pnas.95.5.2061 PMC19248
66 Boyes J Byfield P Nakatani Y Ogryzko V Regulation of activity of the transcription factor GATA-1 by acetylation Nature 1998 396 6711 594 598 9859997 10.1038/25166
67 Hung H-L Lau J Kim AY Weiss MJ Blobel GA CREB-Binding protein acetylates hematopoietic transcription factor GATA- 1 at functionally important sites Molecular and Cellular Biology 1999 19 5 3496 3505 10207073 10.1128/mcb.19.5.3496 PMC84142
68 Hernandez-Hernandez A Ray P Litos G Acetylation and MAPK phosphorylation cooperate to regulate the degradation of active GATA-1 EMBO Journal 2006 25 14 3264 3274 16858405 10.1038/sj.emboj.7601228 PMC1523174
69 Cantor AB Orkin SH Transcriptional regulation of erythropoiesis: an affair involving multiple partners Oncogene 2002 21 21 REV. ISS. 2 3368 3376 12032775 10.1038/sj.onc.1205326
70 Elagib KE Racke FK Mogass M Khetawat R Delehanty LL Goldfarb AN RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation Blood 2003 101 11 4333 4341 12576332 10.1182/blood-2002-09-2708
71 Ferreira R Ohneda K Yamamoto M Philipsen S GATA1 function, a paradigm for transcription factors in hematopoiesis Molecular and Cellular Biology 2005 25 4 1215 1227 15684376 10.1128/MCB.25.4.1215-1227.2005 PMC548021
72 Morceau F Schnekenburger M Dicato M Diederich M GATA-1: friends, brothers, and coworkers Annals of the New York Academy of Sciences 2004 1030 537 554 15659837 10.1196/annals.1329.064
73 Shivdasani RA Molecular and transcriptional regulation of megakaryocyte differentiation Stem Cells 2001 19 5 397 407 11553848 10.1634/stemcells.19-5-397
74 Rekhtman N Radparvar F Evans T Skoultchi AI Direct interaction of hematopoietic transcription factors PU.1 and GATA- 1: functional antagonism in erythroid cells Genes and Development 1999 13 11 1398 1411 10364157 10.1101/gad.13.11.1398 PMC316770
75 Stopka T Amanatullah DF Papetti M Skoultchi AI PU.1 inhibits the erythroid program by binding to GATA-1 on DNA and creating a repressive chromatin structure EMBO Journal 2005 24 21 3712 3723 16222338 10.1038/sj.emboj.7600834 PMC1276718
76 Xiao W Koizumi K Nishio M Tumor necrosis factor- α inhibits generation of glycophorin A + cells by CD34 + cells Experimental Hematology 2002 30 11 1238 1247 12423676 10.1016/s0301-472x(02)00930-x
77 Papadaki HA Kritikos HD Valatas V Boumpas DT Eliopoulos GD Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor- α antibody therapy Blood 2002 100 2 474 482 12091338 10.1182/blood-2002-01-0136
78 La Ferla K Reimann C Jelkmann W Hellwig-Bürgel T Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF- κ B The FASEB Journal 2002 16 13 1811 1813 12223449 10.1096/fj.02-0168fje
79 Imagawa S Nakano Y Obara N A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1 β , TNF- α , or L-NMMA The FASEB Journal 2003 17 12 1742 1744 12958195 10.1096/fj.02-1134fje
80 Tsopra OA Ziros PG Lagadinou ED Disease-related anemia in chronic lymphocytic leukemia is not due to intrinsic defects of erythroid precursors: a possible pathogenetic role for tumor necrosis factor-alpha Acta Haematologica 2009 121 4 187 195 19468203 10.1159/000220331
81 Liu J-J Hou S-C Shen C-KJ Erythroid gene suppression by NF- κ B Journal of Biological Chemistry 2003 278 21 19534 19540 12642582 10.1074/jbc.M212278200
82 Morceau F Aries A Lahlil R Evidence for distinct regulation processes in the aclacinomycin-and doxorubicin-mediated differentiation of human erythroleukemic cells Biochemical Pharmacology 1996 51 6 839 845 8602880 10.1016/0006-2952(95)02240-6
83 Morceau F Chénais B Gillet R Jardillier J-C Jeannesson P Trentesaux C Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells Cell Growth and Differentiation 1996 7 8 1023 1029 8853898
84 Wiley SR Schooley K Smolak PJ Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 1995 3 6 673 682 8777713 10.1016/1074-7613(95)90057-8
85 Snell V Clodi K Zhao S Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies British Journal of Haematology 1997 99 3 618 624 9401075 10.1046/j.1365-2141.1997.4393250.x
86 Bretz JD Rymaszewski M Arscott PL TRAIL death pathway expression and induction in thyroid follicular cells Journal of Biological Chemistry 1999 274 33 23627 23632 10438545 10.1074/jbc.274.33.23627
87 Herr I Wilhelm D Böhler T Angel P Debatin K-M JNK/SAPK activity is not sufficient for anticancer therapy-induced apoptosis involving CD95-L, TRAIL and TNF- α International Journal of Cancer 1999 80 3 417 424 9935184 10.1002/(sici)1097-0215(19990129)80:3<417::aid-ijc14>3.0.co;2-b
88 Jeremias I Herr I Boehler T Debatin K-M TRAIL/Apo-2-ligand-induced apoptosis in human T cells European Journal of Immunology 1998 28 1 143 152 9485194 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3
89 Mariani SM Krammer PH Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage European Journal of Immunology 1998 28 3 973 982 9541592 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-T
90 Walczak H Degli-Esposti MA Johnson RS TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL EMBO Journal 1997 16 17 5386 5397 9311998 10.1093/emboj/16.17.5386 PMC1170170
91 Zang DY Goodwin RG Loken MR Bryant E Joachim Deeg H Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis Blood 2001 98 10 3058 3065 11698291 10.1182/blood.v98.10.3058
92 Campioni D Secchiero P Corallini F Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes American Journal of Pathology 2005 166 2 557 563 15681838 10.1016/S0002-9440(10)62277-8 PMC1602326
93 Silvestris F Cafforio P Tucci M Dammacco F Negative regulation of erythroblast maturation by Fas-L + /TRAIL + highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma Blood 2002 99 4 1305 1313 11830480 10.1182/blood.v99.4.1305
94 Secchiero P Melloni E Heikinheimo M TRAIL regulates normal erythroid maturation through an ERK-dependent pathway Blood 2004 103 2 517 522 12969966 10.1182/blood-2003-06-2137
95 Kolonics A Apáti A Jánossy J Activation of Raf/ERK1/2 MAP kinase pathway is involved in GM-CSF-induced proliferation and survival but not in erythropoietin-induced differentiation of TF-1 cells Cellular Signalling 2001 13 10 743 754 11602185 10.1016/s0898-6568(01)00201-7
96 Jacobs-Helber SM Ryan JJ Sawyer ST JNK and p38 are activated by erythropoietin (EPO) but are not induced in apoptosis following EPO withdrawal in EPO-dependent HCD57 cells Blood 2000 96 3 933 940 10910907
97 Miyazaki R Ogata H Kobayashi Y Requirement of thrombopoietin-induced activation of ERK for megakaryocyte differentiation and of p38 erythroid differentiation Annals of Hematology 2001 80 5 284 291 11446731 10.1007/s002770000285
98 Sui X Krantz SB Zhao ZJ Stem cell factor and erythropoietin inhibit apoptosis of human erythroid progenitor cells through different signalling pathways British Journal of Haematology 2000 110 1 63 70 10930980 10.1046/j.1365-2141.2000.02145.x
99 Maciejewski J Selleri C Anderson S Young NS Fas antigen expression on CD34 + human marrow cells is induced by interferon γ and tumor necrosis factor α and potentiates cytokine-mediated hematopoietic suppression in vitro Blood 1995 85 11 3183 3190 7538820
100 Zoumbos NC Gascon P Djeu JY Young NS Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo Proceedings of the National Academy of Sciences of the United States of America 1985 82 1 188 192 3918301 10.1073/pnas.82.1.188 PMC396997
101 Nakao S Yamaguchi M Shiobara S Interferon- γ gene expression in unstimulated bone marrow mononuclear cells predicts a good response to cyclosporine therapy in aplastic anemia Blood 1992 79 10 2532 2535 1586705
102 Nistico A Young NS Gamma-interferon gene expression in the bone marrow of patients with aplastic anemia Annals of Internal Medicine 1994 120 6 463 469 8311369 10.7326/0003-4819-120-6-199403150-00003
103 Sloand E Kim S Maciejewski JP Tisdale J Follmann D Young NS Intracellular interferon- γ in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia Blood 2002 100 4 1185 1191 12149196 10.1182/blood-2002-01-0035
104 Viale M Merli A Bacigalupo A Analysis at the clonal level of T-cell phenotype and functions in severe aplastic anemia patients Blood 1991 78 5 1268 1274 1715221
105 Zeng W Chen G Kajigaya S Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers Blood 2004 103 1 325 332 14504100 10.1182/blood-2003-02-0490
106 Zeng W Miyazato A Chen G Kajigaya S Young NS Maciejewski JP Interferon- γ -induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles Blood 2006 107 1 167 175 16131564 10.1182/blood-2005-05-1884 PMC1895358
107 Felli N Pedini F Zeuner A Multiple members of the TNF superfamily contribute to IFN- γ -mediated inhibition of erythropoiesis Journal of Immunology 2005 175 3 1464 1472 10.4049/jimmunol.175.3.1464 16034083
108 Bendall LJ Kortlepel K Gottlieb DJ Bone marrow fibroblast exposure to the inflammatory cytokines tumor necrosis factor- α and interferon- α increases adhesion of acute myeloid leukemia cells and alters the adhesive mechanism Experimental Hematology 1997 25 2 132 139 9015213
109 Foley HA Ofori-Acquah SF Yoshimura A Critz S Surendra Baliga B Pace BS Stat3 β inhibits γ -globin gene expression in erythroid cells Journal of Biological Chemistry 2002 277 18 16211 16219 11856732 10.1074/jbc.M106556200
110 Yao X Kodeboyina S Liu L Role of STAT3 and GATA-1 interactions in γ -globin gene expression Experimental Hematology 2009 37 8 889 900 19447160 10.1016/j.exphem.2009.05.004 PMC2746970
111 Rabilloud T Berthier R Vincon M Ferbus D Goubin G Lawrence J-J Early events in erythroid differentiation: accumulation of the acidic peroxidoxin (PRP/TSA/NKEF-B) Biochemical Journal 1995 312 3 699 705 8554508 10.1042/bj3120699 PMC1136170
112 Macciò A Madeddu C Massa D Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia Blood 2005 106 1 362 367 15774616 10.1182/blood-2005-01-0160
113 Mantovani G Macciò A Madeddu C Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status International Journal of Cancer 2002 98 1 84 91 11857390 10.1002/ijc.10143
114 Babbar N Casero RA Jr. Tumor necrosis factor- α increases reactive oxygen species by inducing spermine oxidase in human lung epithelial cells: a potential mechanism for inflammation-induced carcinogenesis Cancer Research 2006 66 23 11125 11130 17145855 10.1158/0008-5472.CAN-06-3174
115 Tewari R Sharma V Koul N Ebselen abrogates TNF α induced pro-inflammatory response in glioblastoma Molecular Oncology 2009 3 1 77 83 19383369 10.1016/j.molonc.2008.10.004 PMC5527871
116 Sattler M Winkler T Verma S Hematopoietic growth factors signal through the formation of reactive oxygen species Blood 1999 93 9 2928 2935 10216087
117 Masutani H Oxidative stress response and signaling in hematological malignancies and HIV infection International Journal of Hematology 2000 71 1 25 32 10729990
118 Smith SC Guilbert LJ Yui J Baker PN Davidge ST The role of reactive nitrogen/oxygen intermediates in cytokine-induced trophoblast apoptosis Placenta 1999 20 4 309 315 10329352 10.1053/plac.1998.0383
119 Greenwald RA Oxygen radicals, inflammation, and arthritis: pathophysiological considerations and implications for treatment Seminars in Arthritis and Rheumatism 1991 20 4 219 240 2042055 10.1016/0049-0172(91)90018-u
120 Chenais B Andriollo M Guiraud P Belhoussine R Jeannesson P Oxidative stress involvement in chemically induced differentiation of K562 cells Free Radical Biology and Medicine 2000 28 1 18 27 10656287 10.1016/s0891-5849(99)00195-1
121 Dallalio G Means RT Jr. Effects of oxidative stress on human erythroid colony formation: modulation by γ -interferon Journal of Laboratory and Clinical Medicine 2003 141 6 395 400 12819637 10.1016/S0022-2143(03)00041-6
122 Elorza A Hyde B Mikkola HK Collins S Shirihai OS UCP2 modulates cell proliferation through the MAPK/ERK pathway during erythropoiesis and has no effect on heme biosynthesis Journal of Biological Chemistry 2008 283 45 30461 30470 18687678 10.1074/jbc.M805400200 PMC2576537
123 Shirihai OS Gregory T Yu C Orkin SH Weiss MJ ABC-me: a novel mitochondrial transporter induced by GATA-1 during erythroid differentiation EMBO Journal 2000 19 11 2492 2502 10835348 10.1093/emboj/19.11.2492 PMC212759
124 Bai Y Onuma H Bai X Persistent nuclear factor- κ B activation in Ucp 2−/− mice leads to enhanced nitric oxide and inflammatory cytokine production Journal of Biological Chemistry 2005 280 19 19062 19069 15757894 10.1074/jbc.M500566200 PMC1382174
125 Kurzrock R The role of cytokines in cancer-related fatigue Cancer 2001 92 6, supplement 1684 1688 11598887 10.1002/1097-0142(20010915)92:6+<1684::aid-cncr1497>3.0.co;2-z
126 Means RT Jr. Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia Stem Cells 1995 13 1 32 37 7719246 10.1002/stem.5530130105
127 Miller CB Jones RJ Piantadosi S Abeloff MD Spivak JL Decreased erythropoietin response in patients with the anemia of cancer New England Journal of Medicine 1990 322 24 1689 1692 2342534 10.1056/NEJM199006143222401
128 Dore LC Amigo JD Dos Santos CO A GATA-1-regulated microRNA locus essential for erythropoiesis Proceedings of the National Academy of Sciences of the United States of America 2008 105 9 3333 3338 18303114 10.1073/pnas.0712312105 PMC2265118
129 Felli N Fontana L Pelosi E MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation Proceedings of the National Academy of Sciences of the United States of America 2005 102 50 18081 18086 16330772 10.1073/pnas.0506216102 PMC1312381
130 Felli N Pedini F Romania P MicroRNA 223-dependent expression of LMO2 regulates normal erythropoiesis Haematologica 2009 94 4 479 486 19278969 10.3324/haematol.2008.002345 PMC2663611
131 Fu Y-F Du T-T Dong M Mir-144 selectively regulates embryonic α -hemoglobin synthesis during primitive erythropoiesis Blood 2009 113 6 1340 1349 18941117 10.1182/blood-2008-08-174854
132 Masaki S Ohtsuka R Abe Y Muta K Umemura T Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis Biochemical and Biophysical Research Communications 2007 364 3 509 514 17964546 10.1016/j.bbrc.2007.10.077
133 Pase L Layton JE Kloosterman WP Carradice D Waterhouse PM Lieschke GJ miR-451 regulates zebrafish erythroid maturation in vivo via its target gata2 Blood 2009 113 8 1794 1804 18849488 10.1182/blood-2008-05-155812 PMC2647672
134 Tili E Michaille J-J Cimino A Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF- α stimulation and their possible roles in regulating the response to endotoxin shock Journal of Immunology 2007 179 8 5082 5089 10.4049/jimmunol.179.8.5082 17911593
135 Wang Q Huang Z Xue H MicroRNA miR-24 inhibits erythropoiesis by targeting activin type I receptor ALK4 Blood 2008 111 2 588 595 17906079 10.1182/blood-2007-05-092718